Abstract
Multiple myeloma (MM) is a plasma cell malignancy that causes devastating bone destruction by activating osteoclasts in the bone marrow milieu. MM is the second of all hematological malignancies. Thus, the search for new pharmacological weapons is under intensive investigation being MM a critically important public health goal. Recently, it has been demonstrated that macrophage inflammatory protein 1- alpha (MIP-1α) is crucially involved in the development of osteolytic bone lesions in MM. Phenolic components of extra virgin olive oil are reported to have anti tumor activity. However, the underlying mechanisms and specific targets of extra virgin olive oil remain to be elucidated. In the present study, we investigated the effects of a recently isolated novel extra virgin olive oil polyphenol, oleocanthal, on the human multiple myeloma cell line ARH-77. Here we report that this natural compound has a remarkable in vitro activity by inhibiting MIP-1α expression and secretion in MM cells. In addition, we also demonstrated that oleocanthal inhibits MM cells proliferation by inducing the activation of apoptosis mechanisms and by down-regulating ERK1/2 and AKT signal transduction pathways. This in vitro study suggests a therapeutic potential of oleocanthal in treating multiple myeloma.
Keywords: Apoptosis, chemokines, multiple myeloma, natural drugs, nutraceuticals, oleocanthal, proliferation.
Current Medicinal Chemistry
Title:Oleocanthal Inhibits Proliferation and MIP-1α Expression in Human Multiple Myeloma Cells
Volume: 20 Issue: 19
Author(s): M. Scotece, R. Gomez, J. Conde, V. Lopez, J.J. Gomez-Reino, F. Lago, A.B. Smith III and O. Gualillo
Affiliation:
Keywords: Apoptosis, chemokines, multiple myeloma, natural drugs, nutraceuticals, oleocanthal, proliferation.
Abstract: Multiple myeloma (MM) is a plasma cell malignancy that causes devastating bone destruction by activating osteoclasts in the bone marrow milieu. MM is the second of all hematological malignancies. Thus, the search for new pharmacological weapons is under intensive investigation being MM a critically important public health goal. Recently, it has been demonstrated that macrophage inflammatory protein 1- alpha (MIP-1α) is crucially involved in the development of osteolytic bone lesions in MM. Phenolic components of extra virgin olive oil are reported to have anti tumor activity. However, the underlying mechanisms and specific targets of extra virgin olive oil remain to be elucidated. In the present study, we investigated the effects of a recently isolated novel extra virgin olive oil polyphenol, oleocanthal, on the human multiple myeloma cell line ARH-77. Here we report that this natural compound has a remarkable in vitro activity by inhibiting MIP-1α expression and secretion in MM cells. In addition, we also demonstrated that oleocanthal inhibits MM cells proliferation by inducing the activation of apoptosis mechanisms and by down-regulating ERK1/2 and AKT signal transduction pathways. This in vitro study suggests a therapeutic potential of oleocanthal in treating multiple myeloma.
Export Options
About this article
Cite this article as:
Scotece M., Gomez R., Conde J., Lopez V., Gomez-Reino J.J., Lago F., Smith III A.B. and Gualillo O., Oleocanthal Inhibits Proliferation and MIP-1α Expression in Human Multiple Myeloma Cells, Current Medicinal Chemistry 2013; 20 (19) . https://dx.doi.org/10.2174/0929867311320190006
DOI https://dx.doi.org/10.2174/0929867311320190006 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Arginine Deprivation as a Targeted Therapy for Cancer
Current Pharmaceutical Design Pegfilgrastim-Apgf (Nyvepria): Biosimilar USFDA Approval for the Treatment of Chemotherapy-induced Febrile Neutropenia and Current Updates on Clinical Trials
Current Drug Targets DNA Repair in Premature Aging Disorders and Neurodegeneration
Current Aging Science Could Resveratrol be a Useful Drug for the Treatment of Malignant Hemopathies?
Recent Patents on Anti-Cancer Drug Discovery The Effects of 5-Aza-2`-Deoxycytidine on DLC-1 Gene Expression, Methylation Level and Expression of Downstream Signaling Molecules Cdc42 in Multiple Myeloma
Current Signal Transduction Therapy Ex Vivo Gene Transfer for Improvement of Transplanted Pancreatic Islet Viability and Function
Current Pharmaceutical Design Synthesis and Biological Study of Novel Indole-3-Imine-2-on Derivatives as Src Kinase and Glutathione S-Transferase Inhibitors
Letters in Drug Design & Discovery Characteristics of Peripheral Blood Stem Cells: 2D-Gel Electrophoresis and Kinetic Parameter of Exocytosis
Current Biomarkers (Discontinued) Tanshinone IIA: Pharmacology, Total Synthesis, and Progress in Structure-modifications
Current Medicinal Chemistry Insights into the Role of Fc Gamma Receptors (FcγRs) Genetic Variations in Monoclonal Antibody-Based Anti-Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Statins as the Controlling Agents for Non-Hodgkin's Lymphomas via Increasing the Casein Kinase 2 Interacting Protein-1: A Hypothesis
Current Drug Discovery Technologies Emerging Family of Protein-protein Interaction Inhibitors Targeting PD-1 Checkpoint Pathway
Current Cancer Therapy Reviews Epigenetically Active Drugs Inhibiting DNA Methylation and Histone Deacetylation
Current Pharmaceutical Design Emerging Concepts on Inhibitors of Indoleamine 2,3-Dioxygenase in Rheumatic Diseases
Current Medicinal Chemistry Current Status and Future Perspectives of PI3K and mTOR Inhibitor as Anticancer Drugs in Breast Cancer
Current Cancer Drug Targets A Review of Depsipeptide and Other Histone Deacetylase Inhibitors in Clinical Trials
Current Pharmaceutical Design The Use of Adenoviral Vectors for Genetic Manipulation and Analysis of Primitive Hematopoietic Cells
Current Gene Therapy Development of Vascular Endothelial Growth Factor Receptor (VEGFR) Kinase Inhibitors as Anti-Angiogenic Agents in Cancer Therapy
Current Medicinal Chemistry Novel Agents Aiming at Specific Molecular Targets Increase Chemosensitivity and Overcome Chemoresistance in Hematopoietic Malignancies
Current Pharmaceutical Design Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery